A detailed history of Squarepoint Ops LLC transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Squarepoint Ops LLC holds 29,109 shares of SWTX stock, worth $1.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,109
Holding current value
$1.14 Million
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$32.04 - $42.76 $932,652 - $1.24 Million
29,109 New
29,109 $932,000
Q1 2024

May 15, 2024

BUY
$36.5 - $52.5 $548,741 - $789,285
15,034 New
15,034 $739,000
Q3 2022

Nov 14, 2022

SELL
$24.1 - $39.66 $229,142 - $377,087
-9,508 Reduced 33.87%
18,560 $530,000
Q2 2022

Aug 15, 2022

BUY
$18.36 - $60.07 $515,328 - $1.69 Million
28,068 New
28,068 $691,000
Q1 2022

May 16, 2022

SELL
$48.97 - $65.46 $520,795 - $696,167
-10,635 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$53.3 - $75.84 $872,734 - $1.24 Million
-16,374 Reduced 60.62%
10,635 $659,000
Q3 2021

Nov 15, 2021

BUY
$62.66 - $88.26 $705,300 - $993,454
11,256 Added 71.45%
27,009 $1.71 Million
Q2 2021

Aug 16, 2021

BUY
$67.45 - $85.63 $195,537 - $248,241
2,899 Added 22.55%
15,753 $1.3 Million
Q1 2021

May 17, 2021

SELL
$65.1 - $93.59 $311,243 - $447,453
-4,781 Reduced 27.11%
12,854 $946,000
Q4 2020

Feb 16, 2021

BUY
$48.36 - $77.92 $483,213 - $778,576
9,992 Added 130.73%
17,635 $1.28 Million
Q3 2020

Nov 16, 2020

SELL
$36.14 - $51.99 $303,973 - $437,287
-8,411 Reduced 52.39%
7,643 $364,000
Q2 2020

Aug 14, 2020

BUY
$22.98 - $48.57 $368,920 - $779,742
16,054 New
16,054 $674,000

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.43B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.